Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
AbbVie 's ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter. AbbVie announced its second-quarter results on July 31. It beat estimates for both earnings and sales. Earnings of $2.97 per share rose 12.1% year over year. Revenues of $15.42 billion rose 6.6% year over year on a reported basis, driven by robust sales of key drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Elahere, Epkinly and Qulipta. Sales of Humira and Imbruvica declined year over year. AbbVie also raised its revenue and EPS guidance for 2025 for the second time this year, backed by a strong momentum in the first half. The company expects adjusted EPS to be in the range of $11.88-$12.08, up from the previous guidance of $11.67-$11.87. Total revenues are expected to be approximately $60.5 billion, higher than the previous expectation of $59.7 billion. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play ABBV stock amid the post-earnings price gain. ABBV's Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for its blockbuster drug, Humira, in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to loss of exclusivity ('LOE') and biosimilar erosion. However, AbbVie has successfully navigated the LOE of Humira by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and are expected to support top-line growth in the next few years. Sales of Skyrizi and Rinvoq have successfully replaced Humira, which once generated more than 50% of its total revenues. Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025. The drugs are seeing strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn's disease (CD). Importantly, Skyrizi and Rinvoq have demonstrated compelling head-to-head data against several novel therapies in clinical studies, which have given them a competitive advantage. Skyrizi sales are now annualizing at almost $18 billion and Rinvoq at over $8 billion. AbbVie expects combined sales of Skyrizi and Rinvoq to be more than $25 billion in 2025 and more than $31 billion by 2027(Skyrizi: more than $20 billion; Rinvoq: more than $11 billion). Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' growth. AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication later this year. In addition, phase III data with Rinvoq in vitiligo are expected later in 2025, followed by hidradenitis suppurativa and systemic lupus erythematosus Phase III readouts in 2026. AbbVie believes that the next wave of potential approvals for Rinvoq could add roughly $2 billion to peak-year sales for the product. ABBV's Growing Oncology Portfolio AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta. Its oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offset the decline in Imbruvica sales. Some key oncology drugs approved in the past couple of years are Epkinly and Emrelis. Elahere was added to AbbVie's oncology portfolio with the February 2024 acquisition of Immunogen. AbbVie is also strengthening its portfolio of oncology medicines with the addition of antibody-drug conjugates or ADCs, which are being considered a disruptive innovation in the pharmaceutical industry. ADCs will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. The company now has two ADCs in its commercial portfolio (i.e., Elahere and Emrelis) and two additional ADCs in late-stage development (ABBV-400 and pivekimab sunirine), along with some others in early-stage development. AbbVie's neuroscience portfolio is also contributing to top-line growth. Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta. AbbVie on an Acquisition Spree AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. AbbVie has executed more than 30 M&A transactions since the beginning of 2024. A key deal was the April 2025 licensing agreement with Denmark's Gubra to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity. The deal marked AbbVie's entry into the obesity space, dominated by Eli Lilly LLY and Novo Nordisk NVO. AbbVie plans to invest further in obesity. AbbVie recently closed the acquisition of privately held biotech Capstan Therapeutics, which will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. ABBV's Slowing Aesthetics Sales & Humira Erosion Sales of AbbVie's blockbuster drug Humira are declining due to biosimilar erosion. The launch of Humira biosimilars in the United States in 2023 significantly eroded the drug's sales in 2024, with the decline being sharper in 2025 as more plans excluded branded Humira and moved to exclusive biosimilar contracts. Humira sales declined more than 50% in the first half of 2025. AbbVie expects Humira's access in the United States to continue to decrease through the second half as more plans select exclusionary formularies for existing patients. AbbVie is seeing declining sales of Juvederm fillers due to continued macro challenges and weakened consumer sentiment. The slowing growth of the U.S. facial injectables market and persistent economic headwinds, which are impacting consumer spending in some countries, including the United States, are hurting sales of Juvederm due to its higher price point. Juvederm sales declined 22.2% in the first half of 2025. ABBV Stock Price, Valuation and Estimate Revision AbbVie's stock has gained 19.3% so far this year against a decrease of 1.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. ABBV Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, AbbVie is not very cheap. Going by the price/earnings ratio, the company's shares currently trade at 15.31 forward earnings, higher than 14.46 for the industry. The stock is cheaper than some other large drugmakers like Eli Lilly, AstraZeneca and J&J, but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.68. ABBV Stock Valuation The Zacks Consensus Estimate for 2025 earnings has declined from $12.03 per share to $12.02, while that for 2026 has increased from $14.08 to $14.31 per share over the past 30 days. ABBV Estimate Movement Stay Invested in ABBV Stock Though AbbVie faces its share of near-term headwinds, the company has faced its biggest challenge — Humira's patent cliff — quite well and looks well-positioned for continued strong growth in the years ahead. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. Sales of AbbVie's ex-Humira drugs rose more than 22% (on a reported basis) in the quarter, driven by Skyrizi, Rinvoq and neuroscience drugs. Boosted by its new product launches, AbbVie expects to return to mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as the company has no significant LOE events for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. With no significant LOEs in this decade, AbbVie enjoys the flexibility to invest more in R&D to continue to acquire external innovation. Rising stock price and estimates (for 2026), its solid pipeline and the fact that it is entering the second half of the year with substantial momentum are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
PROS Recognized as a Gold Stevie® Award Winner in the 2025 International Business Awards®
PROS Holdings, Inc. (NYSE: PRO), a leading provider of AI-powered SaaS pricing and selling solutions, today announced that it was named a winner of a Gold Stevie ® Award in the Business or Competitive Intelligence Solution category in the 22 nd annual International Business Awards ®. This recognition highlighted PROS AI Agents as strong enhancements to the PROS Platform, deeply contextualized to align with each customer's business goals and industry-specific needs. By leveraging advanced natural language processing with PROS prescriptive AI, these intelligent agents interpret and act on data in real time. They operate as intelligent coworkers, streamlining workflows and reducing manual effort across key commercial processes such as pricing, quoting and revenue optimization. 'In a market that shifts by the minute, our AI Agents and the PROS Platform are helping businesses turn complexity into clarity, transforming how they price, sell and serve their customers,' said Jeff Cotten, President and CEO, PROS. 'This win reflects the relentless commitment of our team to deliver AI-powered solutions that enable our customers to make faster, smarter decisions in the moments that matter most.' Judges praised PROS AI Agents for offering a strong approach to AI-powered decision-making and noted the platform's focus on contextual intelligence, automation and actionable insights, which set it apart in a competitive space. One judge added that the PROS Platform 'presents a highly compelling case for innovation in competitive intelligence and pricing optimization,' highlighting its integration of agentic AI for real-time commercial decision-making and its enterprise readiness. The International Business Awards are the world's premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small – are eligible to submit nominations. The 2025 IBAs received nominations from organizations and individuals in 78 nations and territories. Winners will be celebrated during a gala banquet at the Corinthia Hotel in Lisbon, Portugal on Friday, 10 October. For more information about PROS and its award-winning AI solutions, visit About PROS PROS Holdings, Inc. (NYSE: PRO) is a leading provider of SaaS solutions that optimize omnichannel shopping and selling experiences, powering intelligent commerce. Leveraging leadership in revenue and pricing science, the PROS Platform combines predictive AI, real-time analytics and powerful automation to dynamically match offers to buyers and prices to products. Businesses win more with PROS. Learn how at About the Stevie Awards Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards ®, The International Business Awards ®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at
Cision Canada
4 hours ago
- Cision Canada
Silver Miners Enter Parabolic Phase as Analysts Eye $40 Breakout
Issued on behalf of Magma Silver Corp. VANCOUVER, BC, Aug. 20, 2025 /CNW/ -- Silver miners are early in a parabolic move higher as the precious metal pushes toward what analysts describe as a decisive $40 breakout. Industrial demand is creating momentum for the white metal, with fabrication volumes forecast to surpass 700 million ounces for the first time ever in 2025. Market technicians note that silver has cleared key resistance levels while establishing bullish momentum patterns, positioning several miners for potential outperformance, including Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF), Argenta Silver Corp. (TSXV: AGAG) (OTCQB: AGAGF), Endeavour Silver Corp. (NYSE: EXK) (TSX: EDR), Silvercorp Metals Inc. (NYSE-American: SVM) (TSX: SVM), and McEwen Inc. (NYSE: MUX) (TSX: MUX). Multiple investment banks have converged on $40 price targets for silver, with Citigroup, Bank of America, and Saxo Bank citing tightening supply alongside accelerating demand from renewable energy and electronics sectors. Supply deficits are expected to persist for the fifth consecutive year, creating what industry observers call a uniquely compelling backdrop for silver equity leverage plays. Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF) has confirmed that a diamond drilling campaign is expected to begin in Q4 2025 at its strategically positioned Niñobamba project in Peru. The upcoming program will initially target Jorimina, a deposit where Newmont previously invested millions in historic drilling, before expanding to test Randypata and additional high-priority zones. While the company prepares for this pivotal drilling phase, Magma is conducting intensive geological mapping and rock sampling to sharpen drill targets and enhance its structural understanding. With environmental and community consultation requirements now fully satisfied, drill permit approvals are anticipated imminently. "We are excited to start a work program at the advanced Niñobamba silver-gold project focused on the Jorimina and Randypata deposits," said Stephen Barley, Chairman and CEO of Magma Silver. "As announced in our news release dated July 23, 2025, the Tunsulla community access agreement is in place for these two project areas, allowing the Company full access to conduct exploration activities. The work being carried out will assist in refining drill targets for our planned Q4 drill program as well as expand our overall knowledge of the deposits." These crucial access rights were secured through a surface access rights agreement with the Comunidad Campesina De Tunsulla, which remains in good standing through the 2025 season and into 2026. The Jorimina and Randypata deposits represent a compelling exploration target, having attracted over CAD$10 million in historic exploration by Newmont, with standout results including 17.4 metres of 3.06 g/t gold and 128 metres of 1.31 oz/t silver. The broader Niñobamba project encompasses 4,100 hectares and is anchored by three contiguous deposits—Main, Randypata, and Jorimina—believed to form part of an extensive high-sulfidation epithermal system with significant untapped potential. This operational milestone builds on Magma's logistical expansion into Peru, including the establishment of a Lima office and assembly of a seasoned in-country team. Magma's Peru-based operational team includes General Manager Carlos Agreda Minaya, legal counsel Dentons, environmental partner Ecosoul, and field geology expert Edgar Leon Choque. Their immediate priority involves advancing Jorimina toward drilling readiness while simultaneously executing comprehensive mapping and surface work across the mineralized corridor. "The establishment of an experienced operations team we can trust will make a significant contribution to our success in Peru," added Barley. "Peru is a sophisticated, mining-friendly jurisdiction with detailed regulatory requirements that must be strictly adhered to. The experienced team we are involved with will ensure smooth operations for Magma." With a share structure of just over 34 million shares outstanding and all mineral claims secured through mid-2026, Magma is transitioning from asset assembly to active exploration in one of South America's most mining-friendly jurisdictions. As groundwork intensifies and drill targets are finalized, the company stands poised to unlock value from a system that major mining companies spent years defining but never fully developed. In other industry developments and happenings in the market include: Argenta Silver Corp. (TSXV: AGAG) (OTCQB: AGAGF) has delivered exceptional high-grade results from its ongoing drill program at the El Quevar project in Argentina, intercepting 1,026 g/t silver over 40 meters, including an extraordinary 18,467 g/t silver over 1.05 meters. The results demonstrate the exceptional grade continuity and expansion potential of the high-grade silver system at one of Argentina's premier undeveloped silver assets. These intercepts significantly extend the known mineralization and confirm the robust nature of the deposit's silver-rich zones. "These results are exceptional and represent some of the highest-grade silver intercepts we have ever reported at El Quevar," said Joaquín Marías, CEO of Argenta Silver. "The consistency of high-grade silver mineralization across multiple drill holes continues to validate our geological model and reinforces our confidence in the significant resource expansion potential at El Quevar." The company is advancing toward an updated resource estimate while continuing to expand the footprint of high-grade mineralization across the project. Argenta maintains a strong financial position to support ongoing exploration and development activities at this world-class silver asset. Endeavour Silver Corp. (NYSE: EXK) (TSX: EDR) has reported strong Q2 2025 financial results with revenue of $43.4 million and adjusted net income of $2.7 million, driven by silver production of 1.48 million ounces across its Mexican operations. The company achieved consolidated production of 2.53 million silver equivalent ounces, representing a 13% increase year-over-year, while maintaining strong operational performance at its Guanaceví and Bolañitos mines. Endeavour continues to advance its flagship Terronera project toward commercial production, with the operation making significant progress on startup activities and processing optimization. "We delivered strong and consistent production in the second quarter," said Dan Dickson, CEO of Endeavour Silver. "The integration of Kolpa is progressing smoothly, with output already trending above initial expectations. At the same time, Terronera continues to move steadily toward commercial production. This is a pivotal time for Endeavour as we build operational momentum and position the Company for meaningful, long-term growth." The company is positioned for substantial production growth as Terronera ramps toward full commercial production capacity. Endeavour maintains a diversified portfolio of silver-focused operations with significant expansion potential across its Mexican asset base. Silvercorp Metals Inc. (NYSE-American: SVM) (TSX: SVM) has achieved strong Q1 fiscal 2026 results with adjusted net income of $21.0 million and robust cash flow from operating activities of $48.3 million, demonstrating the strength of its silver-focused operations in China. The company produced 1.8 million ounces of silver during the quarter while maintaining its position as one of the few profitable primary silver producers globally. Silvercorp has also received positive regulatory developments in Ecuador, where the Constitutional Court upheld the environmental license for its El Domo silver-gold project. "We are pleased to report another quarter of strong operational and financial performance," said Rui Feng, CEO of Silvercorp. "Our consistent cash generation capabilities continue to support our strategic initiatives while we advance development projects like El Domo in Ecuador, which represents a significant growth opportunity for the company." The company continues to optimize its existing silver operations while advancing development of El Domo, which could become a significant addition to Silvercorp's production profile. Silvercorp maintains a strong balance sheet and proven track record of generating consistent cash flows from its silver-focused mining operations. McEwen Inc. (NYSE: MUX) (TSX: MUX) has reported Q2 2025 results showing continued momentum toward its goal of doubling gold and silver production by 2030, with the company advancing multiple development projects across its portfolio. The quarter demonstrated operational progress at its silver-producing assets, including the San José mine in Argentina and advancement of the Los Azules copper-gold-silver project. McEwen continues to build production capacity while maintaining focus on its precious metals strategy and long-term growth targets. "We continue to make meaningful progress on our strategic goal to double gold and silver production by 2030," said Rob McEwen, Chairman and CEO of McEwen Inc."Our focus remains on advancing our development projects and optimizing our existing operations to create long-term value for shareholders." The company is positioning for significant production growth through development of its Los Azules project and optimization of existing silver operations. McEwen maintains a diversified portfolio of precious metals assets with substantial expansion potential across multiple jurisdictions. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This content is being distributed for media Corp, who has been paid a fee for an advertising contract with Magma Silver Corp. MIQ has not been paid a fee for Magma Silver Corp. advertising or digital media, but the owner/operators of MIQ also co-own Media Corp. ("BAY") There may also be 3rd parties who may have shares of Magma Silver Corp. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of Magma Silver Corp. but reserve the right to buy and sell and will buy and sell shares of Magma Silver Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Magma Silver Corp. Technical information relating to and published by Magma Silver Corp. has been reviewed and approved by Jeffrey Reeder, PGeo, a Qualified Person as defined by National Instrument 43-101. Mr. Reeder is a Technical Advisor of Magma Silver Corp., and therefore is not independent of the Company; this is a paid advertisement, we currently do not own any shares of Magma Silver Corp. but will likely buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
